MedTrace Logo

Clonal Hematopoiesis is a Risk Factor for Chemotherapy-Related Complications

NCT04053439 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 188

Last updated 2025-07-08

No results posted yet for this study

Summary

'CHIP' stands for Clonal Hematopoiesis of Indeterminate Significance, which are mutations in bone marrow stem cells that give that population of cells a survival or 'clonal' advantage for growth. This study investigates whether CHIP in lymphoma patients aged 60 years and older is a risk factor for chemotherapy-related complications like low blood counts, infections, cardiac events, hospitalizations, dose delays and dose reductions, and failure to recover normal blood counts after chemotherapy finishes.

Conditions

Interventions

OTHER

Blood test for determination of CHIP

Patients will have one additional blood draw to be sent for DNA extraction and sequencing for CHIP.

Sponsors & Collaborators

  • The Leukemia and Lymphoma Society

    collaborator OTHER

  • Queen's University

    collaborator OTHER

  • Sunnybrook Health Sciences Centre

    lead OTHER

Principal Investigators

  • Rena Buckstein, MD, FRCPC · Sunnybrook Health Sciences Centre

  • Hubert Tsui, MD · Sunnybrook Health Sciences Centre

  • Michael Rauh, MD · Queen's University

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-08
Primary Completion
2026-01-31
Completion
2026-09-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04053439 on ClinicalTrials.gov